$MANE

Veradermics, Inc

Veradermics is a dermatologist-founded biopharmaceutical company developing treatments for prevalent aesthetic and dermatological conditions. Its lead product candidate, VDPHL01, is an extended-release oral formulation of minoxidil being studied for pattern hair loss in men and women. The company is conducting clinical trials, including three registration-directed trials, and is also evaluating VDPHL01 in an exploratory Phase 2 trial. It has no marketed products described in this profile. Veradermics aims to develop a focused portfolio of aesthetic dermatology candidates, with potential selective development in medical dermatology. It plans to commercialize VDPHL01 directly to patients through a cash-pay model if approved, supported by physician education, advertising and patient engagement. The company retains exclusive worldwide rights to its candidates and may consider strategic collaborations. Veradermics is headquartered in New Haven, Connecticut.

No enriched coverage for $MANE in the last 7 days.

—
$75.2M
ENRIGHT PATRICK G
0%
See all $MANE insider activity →

MANE sentiment & insider activity

Recent MANE coverage spans financial news, insider activity and earnings.

In the last 30 days, MANE insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($75.2M). The most active reporter was ENRIGHT PATRICK G with 2 filings.

What's driving MANE

AlphAI scores every news story that mentions MANE with an AI model for sentiment and relevance, and aggregates insider trades from Veradermics, Inc's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $MANE

Score
$MANEHighAI 9/10Earnings

Veradermics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

Veradermics, Inc (MANE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Veradermics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress Positive topline results from Phase 3 Study ‘304’ and positive 12-month data from Phase 2/3 Study ‘302’ position VDPHL01 to potentially become the first ora

$MANEHighAI 8/10

Veradermics Reports Positive 12-Month VDPHL01 Study Results in Male Hair Loss

Veradermics reported positive 12-month results for VDPHL01 in male hair loss, showing increased hair counts and improved coverage. Twice-daily dosing saw 43.9 hairs/cm² growth, while once-daily had 29.7. The treatment was well-tolerated with no serious adverse events. According to the company, crossover participants from placebo also showed improvements after six months.

$MANEMedAI 8/10Clinical / regulatory· topline data

Veradermics Achieved the Highest VDPHL01 Reported Hair Count in the Phase 3 Program to Date in Positive 12-Month Study '302' Data in Male Pattern Hair Loss

Veradermics, Inc (MANE) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Veradermics Achieved the Highest VDPHL01 Reported Hair Count in the Phase 3 Program to Date in Positive 12-Month Study '302' Data in Male Pattern Hair Loss VDPHL01, a novel orally-administered extended-release minoxidil formulation, demonstrated Target Area Hair Coun

Why This Hair Restoration Biotech's Shares Are Soaring

Veradermics (NYSE: MANE), a biotech company, saw its shares rise 268% post-IPO. Its lead therapy, VDPHL01, showed positive phase 3 trial results, with 78.8% to 85% of patients reporting hair coverage improvements. The drug targets a $30B market for pattern hair loss. The company has $820M in cash and analysts' average price target is $170.

Related tickers